ITL BioMedical, a division of ITL (ASX: ITD) that sets industry standards for the innovative design and production of biological sampling systems for human and animal use, is pleased to announce that after launching its highly innovative patented DonorCare Needle Guard 2 mid-October the Company has already achieved significant sales in excess of one million products.
The product has now been launched and sold in the US and Canada. As well as the considerable sales already made, there are additional customer evaluations being carried out in other geographic regions.
DonorCare Needle Guard 2 (Credit: ITL BioMedical).
ITL has been selling the first generation DonorCare Needle Guard for over 15 years and has sold in excess of 200 million units in over 50 countries.
First generation DonorCare Needle Guard set a global industry standard for whole blood collection needle guards. The highly innovative DonorCare Needle Guard 2 provides robust functionality with enhanced features including visual confirmation the needle is safely locked in place, along with an audible click.
Bill Mobbs, Executive Chairman of ITL BioMedical commented, “It is a great achievement by the team to have made such significant sales in important jurisdictions in such a short period of time. The product was well received at its launch at the AABB Conference in Orlando, Florida and we look forward to announcing further contract wins in the future.”
